Clincosm LogoSign in Get a demo

Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease

Sponsor
Cheng-Hsin General Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT06006819
Collaborator
(none)
155
Enrollment
1
Location
35.7
Anticipated Duration (Months)
4.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Acute heart failure (AHF) is defined as new or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in elderly patients. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is one of the most developed prognostic markers for AHR patients and. NT-pro-BNP has limitations in terms of diagnostic or predictive accuracy in patients with chronic kidney disease (CKD). Plasma proteomics have the potential to examine underlying pathophysiological and prognostic roles, so we compared the plasma proteomic signature to predict outcomes of patients with or without CKD hospitalized for AHF.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    155 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Plasma Proteomic Signature and the Prognosis of Acute Heart Failure With or Without Chronic Kidney Disease
    Actual Study Start Date :
    Jan 1, 2023
    Anticipated Primary Completion Date :
    Dec 23, 2025
    Anticipated Study Completion Date :
    Dec 23, 2025

    Outcome Measures

    Primary Outcome Measures

    1. major adverse cardiovascular events [1 year]

      mortality, acute myocardial infarction, acute stroke, and heart failure hospitalization

    Secondary Outcome Measures

    1. major adverse kidney events [1 year]

      mortality, new end-stage renal disease, and 30% decline in estimated GFR

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • hospitalized for acute heart failure
    Exclusion Criteria:
    • initial serum NT-proBNP level <300ng/ml, pregnancy, amputated, and end-stage renal disease under regular dialysis

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cheng Hsin General Hospital Taipei Baitou District Taiwan 112

    Sponsors and Collaborators

    • Cheng-Hsin General Hospital

    Investigators

    • Principal Investigator: Shang Feng Yang, MD, Cheng-Hsin General Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Shang Feng Yang, Physician, Cheng-Hsin General Hospital
    ClinicalTrials.gov Identifier:
    NCT06006819
    Other Study ID Numbers:
    • CHGH(983)111A-61
    First Posted:
    Aug 23, 2023
    Last Update Posted:
    Aug 23, 2023
    Last Verified:
    Aug 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Kidney Diseases
    Renal Insufficiency, Chronic
    Heart Failure

    Study Results

    No Results Posted as of Aug 23, 2023